Dirk Sibbing: Potent P2Y12 Inhibition in Patients With Atrial Fibrillation and Acute Coronary Syndrome
Dirk Sibbing, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Nature Medicine, adding:
“EPIDAURUS Trial – presented at ESC 2026 and published simultaneously in nature medicine
DOAC plus potent P2Y12 inhibition vs. DOAC plus clopidogrel and in-hospital aspirin in ACS patients (n=602) with atrial fibrillation undergoing PCI
Treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications
Key take: More potent platelet inhibition does not necessarily result in less ischemic events
Clinical scenarios differ in terms of assets and drawbacks of potent platelet inhibition with prasugrel or ticagrelor
Congratulations to Prof. Dr. med. Konstantinos Rizas and Prof. Dr. med. Steffen Massberg at Cardio LMU for the trial lead and for bringing together so many cardiologists for this multi-centre RCT
Please see our results published in Nature Medicine”
Title: Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial
Authors: Konstantinos D. Rizas, Konstantinos Mourouzis, Dominik Rath, Christoph B. Olivier, Laura Elisa Villegas Sierra, Theofanis Korovesis, Amin Polzin, Amani Al Tawil, Reza Wakili, Lukas von Stuelpnagel, Katharina Mayer, Marion Janisch, Tanja Ulrich, Sarah Lang, Sebastian K. G. Maier, Florian Brattinger, Lorenz Bott-Flügel, Harilaos Bogossian, Konstantinos Iliodromitis, Luisa Freyer, Julius Steffen, Konstantin Stark, Elodie Eiffener, Lauren E. Sams, Tobias Petzold, Axel Linke, Felix M. Heidrich, Samuel Sossala, Saif Zako, Nikolaos Dagkonakis, Andreas Schäfer, Frank Edelmann, David M. Leistner, Mariya Maslarska, Fabian Knebel, Georg Nickenig, Blerim Luani, Tienush Rassaf, Hüseyin Ince, Ibrahim Akin, Micha T. Maeder, Meinrad Gawaz, Hans-Josef Feistritzer, Norbert Frey, Stefan Kääb, Riza Sahin, Matthias Pauschinger, Thomas Stiermaier, Ingo Eitel, Marc Kollum, Jan Sebastian Wolter, Michael Schreinlechner, Axel Bauer, Christoph Stellbrink, Ulf Landmesser, Paulus Kirchhof, Dirk Sibbing, Holger Thiele, Adnan Kastrati, Ulrich Mansmann, Steffen Massberg
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 18, 2026, 17:11Owen McCarty: Understanding Prekallikrein and Its Role in Inflammation and Thrombosis
-
Oct 18, 2026, 17:04Emna Gouider Belhadjali: Don’t Miss GPAS 2026 on Bleeding Disorders
-
Oct 18, 2026, 16:53Mehran Ghasemzadeh: Microparticle-Associated Mitochondrial DNA in Stored Platelet Products
-
Oct 18, 2026, 16:38Edward Lee Carter: A 15-Minute Blood Test for Brain Hemorrhage?
-
Oct 18, 2026, 16:29Patrick Taylor: Oral vs Transdermal Estrogen and Cardiovascular Risk in Menopausal Women
-
Oct 18, 2026, 16:19Artangela Henry: A Meaningful Week at the SCDAA National Convention
-
Oct 18, 2026, 16:04Emília Araújo։ New Insights Into the Genetics of Hemophilia B Leyden
-
Oct 18, 2026, 15:43André Marcel Harris: Award-Winning Research on Texas Sickle Cell Data Collection
-
Oct 18, 2026, 15:21Eleonora Gambineri: First Results of the IEI-Haem Consortium at ESID 2026